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Abstract
The androgen receptor (AR) has a central role in development and maintenance of the male reproductive system and in the
etiology of prostate cancer. The transcription factor Pax6 has recently been reported to act as a repressor of AR and to be
hypermethylated in prostate cancer cells. SPBP is a transcriptional regulator that previously has been shown to enhance the
activity of Pax6. In this study we have identified SPBP to act as a transcriptional coactivator of AR. We also show that Pax6
inhibits SPBP-mediated enhancement of AR activity on the AR target gene probasin promoter, a repression that was partly
reversed by increased expression of SPBP. Enhanced expression of Pax6 reduced the amount of SPBP associated with the
probasin promoter when assayed by ChIP in HeLa cells. We mapped the interaction between both AR and SPBP, and AR and
Pax6 to the DNA-binding domains of the involved proteins. Further binding studies revealed that Pax6 and SPBP compete
for binding to AR. These results suggest that Pax6 represses AR activity by displacing and/or inhibiting recruitment of
coactivators to AR target promoters. Understanding the mechanism for inhibition of AR coactivators can give rise to
molecular targeted drugs for treatment of prostate cancer.
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Introduction
The androgen receptor (AR) and androgens have a central role
in development and maintenance of the male reproductive system
and in the etiology of prostate cancer [1,2], the most commonly
diagnosed invasive cancer in men in the USA and other western
countries [3]. Since prostate cancers are dependent on androgens
for development, growth and survival, inhibition of AR activity is a
major therapeutic goal for management of the disease (reviewed in
[4]). Unliganded AR is mainly localized to the cytoplasm through
interactions between its ligand binding domain (LBD) and heat-
shock proteins (HSPs). Binding of androgens to the LBD induces
conformational changes that cause dissociation of the HSPs [2].
The receptor subsequently dimerizes and becomes phosphorylat-
ed, before the receptor-steroid complex is imported into the
nucleus. Here it binds with high affinity to specific DNA-
regulatory elements of target genes [1]. The context of the
promoter and the relative levels of coactivators and corepressors
determine the resulting transcriptional outcome of the DNA
bound receptor [5]. AR has four functional domains; the divergent
N-terminal domain (NTD), a central DNA-binding domain
(DBD), a hinge-region, and a C-terminal LBD [1,2]. The NTD
contains poly-glutamine and -glycine repeats as well as the
transcriptional activation function-1 site (AF-1) that is constitu-
tively active independent of androgens [6]. The LBD has a second
activator function site (AF-2) that is only active in the presence of
androgens [2]. Both AF-1 and AF-2 can activate AR, whereas
interactions between them can modulate its activity [7].
Stromelysin-1 PDGF-responsive element Binding Protein
(SPBP) is a 220 kDa nuclear protein displaying structural and
functional properties of a transcriptional regulator. It contains an
N-terminal TAD, three nuclear localization signals (NLS), a DBD
containing an AT-hook motif, and a C-terminal extended plant
homeodomain (ePHD) [8]. SPBP enhances the activity of the
transcription factors c-Jun, Pax6, Sp1 and Ets1 [8,9], and
knockdown of SPBP significantly reduces the expression of the
Ets1 target gene MMP3 in cells [10]. SPBP has also been identified
as an interaction partner for activated Estrogen Receptor a (ERa),
and found to work as a corepressor of this particular steroid
hormone [11]. Further, SPBP is shown to bind and enhance the
activation potential of the transcriptional cofactor RNF4 [12].
RNF4 was originally identified as a coactivator of AR, enhancing
both basal and ligand-induced AR-mediated transcriptional
activity [13].
Pax6 is an evolutionary conserved transcription factor consisting
of two DBDs, the paired domain (PD) and the paired-type
homeodomain (HD), separated by a glycine-rich linker sequence
[14–16]. In addition, a TAD is located in the C-terminal region
[17]. The N-terminal PD is structurally and functionally divided
into the PAI and RED subdomains [18,19]. These subdomains, as
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independently to DNA [19]. The PD can also bind to the HD of
Pax6, and to other HD containing proteins [20,21]. Pax6 is
important for embryogenesis of the eye, brain, spinal cord,
pancreas, and olfactory epithelium [14,16,22]. The developmental
role of Pax6 and the other Pax family proteins has been established
for quite some time. More recently, it has been acknowledged that
PAX genes are expressed in cancer cells and tissues where they are
not normally found [23]. While most Pax family members are
associated with an unfavorable outcome of the cancer, Pax6 has
been proposed to have a tumor suppressor function in both
glioblastoma [24–28] and prostate cancer [29].
In this study, we have identified SPBP as a transcriptional
coactivator of AR. SPBP interacts with the DBD of AR via its own
DBD. We also mapped the interaction between AR and the AR
repressor and developmental transcription factor Pax6 to involve
their respective DBDs. Importantly, Pax6 inhibited the SPBP-
mediated enhancement of AR activity on the AR targeted probasin
promoter. This repression was partly reversed by increased
expression of SPBP. Chromatin immunoprecipitations showed that
over-expression of Pax6 resulted in less SPBP associated with the
probasin promoter. In vitro binding studies revealed that Pax6 and
SPBPcompetefor bindingto the AR(DBD). This suggests that Pax6
represses AR activity by displacing and/or inhibiting recruitment of
coactivators to AR target promoters.
Materials and Methods
Plasmid constructs
Plasmids and primers used in this study are listed in Tables S1
and S2, respectively. Details on their construction are available on
request. Primers for PCR and DNA sequencing were purchased
from Eurogentec and Operon. PCR amplification of cDNA was
done using either Pfu Turbo (Stratagene) or ExTaq (TaKaRa)
polymerases. Many of the plasmids were made using the Gateway
cloning system (Invitrogen). All constructs were verified by DNA
sequencing with BigDye v3.1 (Applied Biosystems).
Cell lines
HeLa (ATCC CCL2), Du145, and B3 (ATCC CRL-11421) cells
were grown in Eagle’s minimum essential medium (MEM).
HEK293 (ATCC CRL-1573), SKNBe(2), and MEF cells were
grown in Dulbecco’s modified Eagle’s medium (DME). PC3 cells
were grown in Ham’s F12K supplemented with 1.5 g/l sodium
bicarbonate, while Kelly and LNCaP cells were grown in RPMI
1640 medium. The medium for the LNCaP cells were supplement-
ed with 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM
HEPES, and 0.1 mM sodiumpyruvate. The GFP-AR 3108 cell line
[30] was maintained in DME supplemented with 1 mg/ml G418,
0.55 mg/ml puromycin and 10 mg/ml tetracycline. Stable 36Flag-
Pax6 transfected HeLa cells were generated using the FlpIn
recombinant system (Invitrogen) according to the manufacturer’s
protocol. The HeLa FlpIn 36Flag-Pax6 cells were grown in DME
with 4 mg/ml blasticidin and 200 mg/ml hygromycin. In addition,
the media for all cell lines were supplemented with 10% fetal bovine
serum (Biochrom AG, S0615) and 1% streptomycin-penicillin
(Sigma, P4333). Cultured cells were maintained at 37uC with 95%
air and 5% CO2 in a humidified atmosphere.
Reporter gene assays
Subconfluent HEK293 or LNCaP cells in 24-well tissue culture
dishes (Becton Dickinson) were transiently transfected using
Metafectene Pro (Biontex) according to the manufacturer’s
protocol. The cells were cultured in 5% charcoal treated serum
one day before transfection. Medium with 0.5% charcoal treated
serum and 10
27 M synthetic androgen R1881 (Perkin-Elmer) was
(if indicated) added to the cells 1 hour before transfection. All wells
were cotransfected with 75 ng pDestHA-AR, 75 ng of the
luciferase reporter p285PB-Luc [31], and 5 ng pCMV-b-galacto-
sidase (Stratagene). In addition, the HEK293cells were cotrans-
fected with 0–25 ng pDestHA-Pax6, and 50 or 150 ng pDestHA-
SPBP, as indicated in Figure 1A. The LNCaP cells were in
addition cotransfected with 5–200 ng pDestHA-Pax6 as indicated
in Figure 1B. pcDNA3HA (Invitrogen) was used to equalize the
concentration of DNA in each transfection. Extracts were
prepared 20 hours after transfection using a Dual-Light luciferase
and b-galactosidase reporter gene assay system (Tropix), and
subsequently analyzed in a Labsystems Luminoskan RT dual
injection luminometer. The assays were performed in triplicates
and repeated at least three times.
Immunoblotting of whole cell extracts
Whole cell extracts were prepared by adding 400 ml lysis buffer
(1% SDS; 10 mM TrisHCl pH 7.5; 90uC) to confluent cells in
10 cm culture dishes (Nunc). The lysates were sonicated,
centrifuged, and stored at 270uC. The protein concentration
was measured with a BioRad DC protein assay kit. Fifty mg of each
lysate was run on 6 or 12% SDS-polyacrylamide gels (SDS-PAGE)
in Tris-Glycine buffer (25 mM Tris, 250 mM glycine, 0.1% SDS).
Biotinylated Protein Ladder (Cell Signalling) was used as a
molecular weight marker. The proteins were subsequently
immunoblotted on Hybond-ECL nitrocellulose membranes
(Amersham) in Towbin buffer (25 mM Tris, 192 mM glycine,
20% methanol) at 100 V for 1 hour. The membranes were
blocked in 5% non-fat dried milk for 1 hour at room temperature.
Primary antibody was added overnight at 4uC. The primary
antibodies used were rabbit anti-Pax6 (1:1.000, Millipore), mouse
anti-AR (1:100, Santa Cruz), rabbit anti-SPBP (1:500, [10]),
mouse anti-HA (1:1.000, clone 12CA5, Roche) and rabbit anti-b-
actin (1:1.000, Sigma-Aldrich). Secondary antibodies, HRP-
conjugated anti-mouse or anti-rabbit IgG (1:2.000, Pierce) and
anti-Biotin (1:2.000, Cell Signalling), were added for 1 hour at
room temperature. Detection was performed using Western blot
luminol reagent (Santa Cruz Biotechnology) and a LumiAnalyst
imager (Roche Applied Sciences).
Chromatin Immunoprecipitation
Subconfluent HeLa cells in 10 cm dishes were transiently
transfected with 2.25 mg of p285-PBLUC [31], pDestHA-AR and
pDestHA-SPBP using Metafectene Pro (Biontex). In addition,
some dishes were co-transfected with 300 ng or 1.5 mg pDestHA-
Pax6 as indicated in Figure 1D. Five hours post transfection the
cells were stimulated by 10
27 M synthetic androgen R1881
(Perkin-Elmer). Sixteen hours post transfection the cells were
harvested and chromatin immunoprecipitation was performed
essentially as described previously [10]. Primers used to amplify
precipitated probasin promoter were 285PB-Luc-fw and 285PB-
Luc-rev (Table S2).
Real-Time PCR
Subconfluent LNCaP cells in 6 well dishes were tansfected with
20 nM SPBP siRNA [10] or scrambled siRNA [10] using
RNAiMAX (Invitrogen). The cells were stimulated by R1881
(10
27 M) for 48 hours post transfection. RNA was isolated using
RNAeasy Plus Minikit (QIAGEN), cDNA made using Transcrip-
tor Universal cDNA Master (Roche), and RT-PCR performed on
a STRATAGENE 6300 amplification system using FastStart
Universal SYBR Green Master (Roche). Primers were PSA-fw,
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run for an initial step at 95uC for 10 min, followed by 40 cycles of
amplification at 95uC for 15 s and 60uC for 1 min. All data were
collected during the extension step, and a melting curve was
obtained at the end of the PCR reaction to verify that only one
product was produced.
Confocal microscopy
GFP-AR expression was induced from the GFP-AR 3108 cell
line by removing the tetracycline from the medium 3 days before
the experiments were performed. G418 and puromycin were also
removed from the medium to improve the expression. The cells
were cultured in 8-chambered cover slides (Nunc) and transiently
transfected with 100 ng pDestCherry-Pax6 or 150 ng pDestCh-
erry-SPBP using TransIT-LT1 (Mirus Bio) according to the
manufacturer’s protocol. As described previously, the cells were
starved in medium with charcoal-treated serum and hormone
induced with R1881. Subconfluent HeLa cells in 8-well coverglass
slides were transiently co-transfected with 175 ng pDestEGFP-
SPBP and 25 ng pDestmCherry-Pax6 using TransIT-LT1. Live
cell images were taken the following day after transfection using a
Zeiss LSM510 confocal laser scanning microscope. Colocalization
was studied using the Zeiss LSM 510 software.
Coimmunoprecipitation
For coimmunoprecipitation of AR and Pax6, expression of
36Flag-Pax6 was induced from HeLa FlpIn 36Flag-Pax6 cells by
adding 1 mg/ml tetracycline. Subconfluent cells in 10 cm dishes
(Nunc) were transiently transfected with either pDestEGFP-AR or
pEGFP-C1 using Metafectene Pro (Biontex) according to the
manufacturer’s protocol. R1881 (10
27 M) was added to stimulate
the AR. For coimmunoprecipitation of AR and SPBP, 2610
5 HeLa
Figure 1. Pax6 represses SPBP-mediated enhancement of AR
activity. (A) Pax6 represses AR-mediatedexpressionfromthe285PB-Luc
reporter. LNCaP cells were cultured in medium with charcoal treated
serum and cotransfected with 5–200 ng pDestHA-Pax6, 75 ng pDestHA-
AR, 75 ng p285PB-Luc, and 5 ng pCMV-bgal using Metafectene Pro
(Biontex). pcDNA3HA was used to equalize the amount of DNA in each
well. 10
27 M synthetic androgen (R1881) was added as indicated. The
mean luciferase/b galactosidase value of AR-mediated expression from
285PB-Luc after stimulation with R1881 was setto 1.Thedata is based on
the mean values of three independent experiments performed in
triplicate. (B) SPBP enhances AR-mediated expression, a coactivation that
is lost by coexpression of Pax6. HEK293 cells were cultured in medium
with charcoal treated serum and cotransfected with 75 ng pDestHA-AR,
50 or 150 ng pDestHA-SPBP, 0–25 ng pDestHA-Pax6, 75 ng p285PB-Luc,
and 5 ng pCMV-bgal. The experiment was performed and data obtained
as described in A. (C) Chromatin Immunoprecipitation assays show that
both SPBP and AR associate with the probasin promoter, and that
overexpression of Pax6 decreases the amount of SPBP associated with
the promoter. Extracts from HeLa cells cotransfected with 285PB-Luc,
pDestHA-SPBP, pSG5-AR, and/or increasing amounts of pDestHA-Pax6
were immunoprecipitated with preimmune serum, polyclonal anti-SPBP
antibody or polyclonal anti-AR antibody. PCR analyses on the immuno-
precipitated chromatin were carried out using primers flanking the
probasinpromoter(upperpanel).Primersaligningtoposition-3351and-
3069 of the cathepsin D promoter were used as control (lower panel).The
1 kb DNA ladder is shown to the left. (D) SiRNA knock down of
endogenous SPBP in R1881 stimulated LNCaP cells reduces the
expression of the AR target gene PSA. LNCaP cells were transfected with
SPBP siRNA or scrambled siRNA, stimulated with R1881 for 48 hours
before harvesting. RT-PCR reactions were run on PSA and b-actin mRNA.
The average amount of PSA mRNA correlated to b-actin mRNA based on
four independent experiments are shown with standard deviations. The
right panel shows the knock-down of SPBP expression in LNCaP cells
transfected with SPBP siRNA compared to scramled siRNA transfected
and untransfected LNCaP cells.
doi:10.1371/journal.pone.0024659.g001
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charcoal treated serum, and incubated for 18–20 hours. The cells
were then transiently cotransfected with 3 mg pDestEGFP-AR and
7 mg pDestHA-SPBP, using the Calcium Phosphate transfection
procedure [32]. 3–4 hours after transfection, the cells were
stimulated using R1881 (10
27 M). The cells from both experiments
were harvested 20 hours post transfection and immonoprecipitaed
essentially as described [10]. Primary antibodies used in the western
blot were mouse anti-Flag M2 (1:5.000; Stratagene), rabbit anti-
SPBP (1:500, [10]) or rabbit anti-GFP (1:1.000; Abcam).
For in vitro coimmunoprecipitation assays, expression vectors
pDestHA-SPBP and pDest53-AR were in vitro translated in the
presence of
35S-methionine and immunoprecipiated as described [10].
Fluorescence resonance energy transfer (FRET)
FRET with photobleaching of the acceptor was done using a
Zeiss LSM510 META confocal microscope as described [20].
HeLa cells were cotransfected with 50 ng of both CFP- and YFP-
tagged expression constructs using LipofectAmine PLUS (Invitro-
gen). Three to five cell nuclei expressing a 1:1 ratio of the CFP-and
YFP-tagged proteins were examined per protein pair. A CFP-YFP
fusion protein with a linker of 52 residues (pDestECFP-re7-EYFP),
and a CFP-Pax6-YFP fusion protein (pDestECFP-Pax6-EYFP)
were used as positive FRET controls. The following protein pairs
were used as negative controls: CFP (pDestECFP-C1) and YFP
(pDestEYFP-C1), CFP-AR (pDestECFP-AR) and YFP, and CFP
and Pax6-YFP (pDestPax6-EYFP). Percent FRET efficiency
between CFP- and YFP-tagged proteins was calculated as the
difference between CFP fluorescence before and after bleach using
the formula: ((A1–A0)/A1)–((B1–B0)/B1)/BkYFP-Pax66100%.
A1 and A0 are CFP emission in the region of interest (ROI) in
the bleached cell after and before photobleaching, while B1 and
B0 are CFP emission in a non-bleached ROI in a control cell after
and before photobleaching, respectively [33]. The bleach constant
Bk for YFP-Pax6 was experimentally found to be 0.68.
GST and MBP pulldown assays
GST and GST fusion proteins were expressed in Escherichia coli
BL21STAR (lDE3) pLysS (Novagen) and purified from extracts
using glutathione-sepharose 4 fast flow beads (Amersham
Biosciences). MBP and MBP fusion proteins were expressed in
E. coli DH5a and purified on amylose resin (New England
Biolabs). In vitro translation and dilution of
35S-labeled proteins
were performed as described for in vitro coimmunoprecipitation.
GST or MBP bound to beads were added to the samples for
30 minutes at 4uC on a rotating wheel to remove unspecific
binding. The supernatants were subsequently mixed with 1–2 mg
of the indicated fusion proteins immobilized on beads and
incubated at 4uC for 1 hour. After 5 times washing in NET-N
buffer, the beads were resuspended in 26SDS gel loading buffer
and boiled for 5 minutes. If indicated, 10
27 M synthetic androgen
R1881 was added to the reactions. The samples were separated on
10% SDS-PAGE gels together with a molecular weight marker
(New England Biolabs #P7703S), stained with Coomassie brilliant
blue (CBB) and vacuum dried. Signal from
35S-labeled proteins
was detected with a Fujifilm bioimaging analyzer FUJI-BAS5000.
Results
Pax6 represses SPBP-mediated enhancement of AR
activity
Recent reports show Pax6 to be a repressor of AR activity [29],
and the PAX6 gene to be hypermethylated in prostate cancer cells
[34]. p285PB-Luc contains a fragment of the AR targeted rat
probasin promoter upstream of the luciferase gene [31]. Using
p285PB-Luc as a reporter, we confirm that Pax6 represses AR-
mediated transactivation in LNCaP prostate cancer cells
(Figure 1A). These results correlate well with other reports
suggesting Pax6 to have a tumor suppressor function [24–28].
We have previously found that the nuclear protein SPBP acts as a
coactivator of Pax6 [8]. Interestingly, SPBP also interacts with
phosphorylated ERa and represses its transcriptional activity [11].
These results encouraged us to investigate whether Pax6 and SPBP
together would have any impact on AR activity. To this end,
luciferase reporter gene assays were performed in HEK293 cells
using p285PB-Luc as a model system. Figure 1B shows that SPBP
alone enhanced the transcriptional activity of AR in a dose
dependent manner, hence acting as a transcriptional coactivator of
AR. Coexpression of SPBP and increasing concentrations of Pax6
resulted in corresponding increased repression of the SPBP-
mediated enhancement of AR activity. However, increasing ectopic
expression ofSPBP seemstopartlyrestoretheactivitysuppressed by
Pax6, suggesting a competitional recruitment to AR.
Chromatin immunoprecipitation assays were performed to
investigate whether SPBP was recruited to the AR target promoter
probasin, and if Pax6 could affect this recruitment. In order to
obtain expression of the three proteins in the same cells, with
varying amounts of Pax6, HeLa cells were cotransfected with the
probasin-luciferase promoter construct and vectors expressing AR,
SPBP and/or Pax6. The results presented in Figure 1C (upper
panel) clearly show that SPBP and AR are associated with the
same fragment of the probasin promoter. Furthermore, expression
of increasing amounts of Pax6 reduces the amount of SPBP
associated with the promoter. An upstream fragment of the
Cathepsin D promoter was amplified on the same samples to
verify specificity (Figure 1C, lower panel). Hence, Pax6 seems to
inhibit recruitment of SPBP to the AR target probasin promoter.
AsshowninFigure1B,SPBPenhancesARactivityonlymodestly
in reporter gene assays using exogenous proteins. To determine
whether SPBP has an effect on the expression of an endogenous AR
target gene, SPBP siRNAs were transfected into LNCaP cells
followed by monitoring the expression level of PSA mRNA by RT-
PCR. SPBP expression is highly knocked down by the SPBP
siRNAs (Figure 1D, right panel). Importantly, PSA mRNA is
reduced to approximately 40% in the SPBP knock down cells
compared to scrambled siRNA (Figure 1D, left panel). These results
show that SPBP enhances expression of AR target genes also in an
endogenous system. The modest effect of SPBP in the reporter gene
system may be due to low expression levels of exogenous SPBP
compared to exogenous Pax6 and AR (Figure S1).
Together, these results show that SPBP acts as a potent
transcriptional coactivator of AR, while Pax6 acts as a repressor
inhibiting recruitment of SPBP to the AR target promoter and
thereby reduces the SPBP-mediated enhancement of AR activity.
AR, SPBP and Pax6 display a very similar nuclear
distribution pattern in androgen stimulated cells
To further evaluate the putative association among Pax6, SPBP
and AR, their nuclear distribution patterns were investigated by
confocal laser scanning microscopy. The mammary adenocarci-
noma cell line GFP-AR 3108 stably expressing GFP-AR [30] was
transiently transfected with plasmids expressing Cherry-Pax6 or
Cherry-SPBP (Figure 2A and 2B, respectively). Both Cherry-Pax6
and Cherry-SPBP strongly colocalized with GFP-AR in the
nucleus of nearly all 3108 cells upon synthetic androgen (R1881)
stimulation. The proteins are located throughout the nucleus
except from the nucleolus, in a subnuclear localization pattern we
have previously denoted as chromatin-rich, nuclear territories
Mechanism of Pax6-Mediated Repression of AR
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overexpressing EGFP-AR and Cherry-Pax6 or Cherry-SPBP (data
not shown). In line with this, Pax6 and SPBP were found to
colocalize almost completely in the nucleus of all transfected HeLa
cells (Figure 2C). Lack of available Pax6 and SPBP antibodies that
work well in immunostaining, made it difficult to study the
distribution pattern of the endogenous proteins. However,
colocalization was assayed on cells that displayed moderate levels
of the exogenous proteins. Furthermore, calculation of the
Pearson’s correlation coefficient of several cells resulted in an
average correlation coefficient of 0.7 for Pax6 and AR, SPBP and
AR, and Pax6 and SPBP (Figure 2D). Taken together, these results
strongly suggest that AR, Pax6 and SPBP are enriched in the same
chromatin-rich territories of R1881 stimulated human cells.
Figure 2. Colocalization and coexpression of AR, Pax6 and SPBP. (A) and (B) Colocalization between GFP-AR and Cherry-Pax6 or Cherry-SPBP,
respectively. The GFP-AR 3108 expressing cell line [30] was transiently transfected with 100 ng pDestCherry-Pax6 or 150 ng pDestCherry-SPBP using
TransIT-LT1 (Mirus Bio). The cells were stimulated with synthetic androgen R1881 and live cell images obtained using a Zeiss LSM510 confocal laser
scanning microscope. Scale bars: 10 mm. (C) Colocalization between GFP- and Cherry-tagged SPBP and Pax6. HeLa cells were transiently cotransfected
with either 175 ng pDestEGFP-SPBP and 25 ng pDestCherry-Pax6, or 25 ng pDestEGFP-Pax6 and 175 ng pDestCherry-SPBP using TransIT-LT1 (Mirus
Bio). Live cell images were obtained as in A. Scale bars: 10 mm. (D) Pearson’s correlation coefficients support the colocalization of GFP-AR with
mCherry-SPBP and mCherry-Pax6 shown in A and B. The correlation is based on the average of 5–10 independent cells, with standard deviations
shown. The nuclear correlation between mCherry-Pax6 and nuclear GFP, and GFP-Pax6 and nuclear mCherry, were used as negative controls. (E)
Coexpression of Pax6, SPBP and AR in mammalian cell lines. Approximately 50 mg proteins from each of the whole cell extracts were separated on 6
and 12% SDS-polyacrylamide gels, followed by immunoblotting using anti-Pax6 (Chemicon), anti-AR (Santa Cruz), anti-SPBP [10] and anti-actin
(Sigma) antibodies. Actin was used as a loading control. The cell lines used were HeLa (human epithelial), HEK293 (human embryonic kidney), MEF
(mouse embryonic fibroblast), Kelly and SKNBe(2) (human neuroblastoma), and Du145, PC3 and LNCaP (human prostate cancer).
doi:10.1371/journal.pone.0024659.g002
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cells, whole cell extracts from nine different cell lines were
analyzed by immunoblotting using antibodies against Pax6, SPBP
and AR. The blots in Figure 2E show that SPBP is expressed in all
of the cell lines tested, while Pax6 is expressed in HeLa, HEK293,
B3 and PC3 cells. Expression of Pax6 in the B3 cell line was not
unexpected, given that it is a human lens epithelial cell line. We
also detected Pax6 at very low levels in Du145 and the human
neuroblastoma cell line SKNBe(2), while no expression was
detected in the mouse embryonic fibroblasts (MEFs) or the human
prostate cancer cell line LNCaP. In contrast, high expression of
AR was, as expected, detected in the latter cell line. Human
Du145 and PC3 prostate cancer cells are frequently used as AR
negative control cells, but we detected some expression of AR in
these cell lines as well. AR was also expressed in HeLa, HEK293,
Kelly and B3 cells at very low levels, but was not detected in the
MEF or SKNBe(2) cell lines. In summary, Pax6, SPBP and AR are
coexpressed in the B3 lens epithelial and PC3 prostate cancer cell
lines. Interestingly, SPBP is highly expressed in the AR positive
prostate cancer cell line LNCaP. SPBP is also expressed in
glandular cells of the prostate and in 30% of prostate cancer
samples in the Human Protein Atlas (www.proteinatlas.org). This
correlates well with the expression pattern of AR and several AR
target genes such as PSA, Elk4 (Sap-1a) and the AR-coactivator
LSD1 (www.proteinatlas.org, [36]).
FRET analysis reveals a direct interaction between AR and
Pax6 in cells
Recently, an association between Pax6 and AR in COS-1 cells
has been reported [29]. To evaluate if this interaction is direct in
human cells, FRET experiments were performed using the
acceptor photobleaching method as previously described [20,33].
HeLa cells were cotransfected with expression constructs for Pax6
and AR tagged with yellow (YFP) and cyan (CFP) fluorescent
proteins, respectively. With the CFP and YFP fluorescent proteins,
FRET only occurs within a distance of 10 nm [37]. The CFP-AR
and Pax6-YFP fusion proteins are schematically illustrated in
Figure 3A before and after photobleaching. As shown in Figure 3B,
Figure 3. Pax6 and AR interact directly in vivo. (A–C) FRET between Pax6 and AR. HeLa cells transiently expressing a 1:1 ratio of CFP-AR
(pDestECFP-AR) and YFP-Pax6 (pDestPax6-EYFP) were subjected to FRET as described in the methods section. A schematic illustration of CFP-AR and
YFP-Pax6 before and after acceptor photobleaching is presented in A. The cell images in B are visualized in pseudo-colors before and after acceptor
photobleaching. The YFP acceptor was bleached, and FRET detected as decreased YFP-emission at 532 nm and a corresponding increased CFP-
emission at 479 nm in the bleached area. The graphical display in B shows the emission spectrum of CFP-AR together with YFP-Pax6 at 479 and
532 nm, respectively, before (blue) and after (red) acceptor photobleaching. (C) Percent FRET between CFP-AR and Pax6-YFP compared with FRET
between CFP-YFP, CFP-Pax6-YFP, and CFP-Pax6 - Pax6-YFP. The FRET efficiency was calculated as described in the methods section. Each bar
represents the mean of 3–5 experiments. (D) Coimmunoprecipitation of GFP-AR and 36Flag-Pax6. HeLa FlpIn 36Flag-Pax6 cells were induced to
express 36Flag-Pax6 and subsequently transfected with pDestEGFP-AR or pEGFP-C1 using Metafectene Pro (Biontex). A GFP-antibody (Abcam) was
used to immunoprecipitate GFP-AR-36Flag-Pax6 complexes from the cells. The upper right gel shows the 0.5% input of 36Flag-Pax6 and the lower
right gel the 0.5% input of GFP and GFP-AR. The upper left gel shows that 36Flag-Pax6 was immunoprecipitated together with GFP-AR, but not with
the GFP control.
doi:10.1371/journal.pone.0024659.g003
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24659strong FRET was detected between Pax6 and AR in the nuclei of
HeLa cells. Figure 3C shows the calculated percent FRET
efficiencies. A FRET efficiency of 2163.7% was detected between
the CFP-Pax6 and Pax6-YFP fusion proteins, while the FRET
efficiency between Pax6-YFP and CFP-AR was 14.861.5%. A
CFP-YFP fusion protein with a linker of 52 non-specific amino
acids separating CFP and YFP was used as a positive control,
yielding a FRET efficiency of 27.560.4%. Another positive
control, CFP-Pax6-YFP, gave a FRET efficiency of 23.362.9%.
CFP versus YFP, CFP-AR versus YFP, and CFP versus Pax6-YFP
were used as negative controls and displayed little or no FRET
(data not shown). The results from the FRET experiments clearly
show that Pax6 and AR bind directly to each other in the nucleus
of living human cells. This was further confirmed by coimmuno-
precipitation of EGFP-AR and 36Flag-Pax6 from HeLa FlpIn
cells (Figure 3D). Expression of Flag-tagged Pax6 was induced by
adding tetracycline to the medium, before the cells were
transiently transfected with plasmids expressing EGFP-AR. AR
was stimulated by adding synthetic androgen to the medium, and
a GFP-antibody was used to immunoprecipitate GFP-AR-36Flag-
Pax6 complexes from the cells. The upper left panel in Figure 3D
shows that 36Flag-Pax6 was immunoprecipitated with GFP-AR,
but not with the GFP alone. This further confirms the AR-Pax6
interaction established with the FRET assays.
The PD of Pax6 binds to the DBD of AR
Next, pulldown assays were performed in order to map the
interacting regions of AR and Pax6. The various domains of both
proteins,asindicatedinFigure4Aand C,wereexpressedasGSTor
MBP fusion proteins in E. coli, while the full-length proteins were in
vitro translated in the presence of
35S-methionine. The GST
pulldown assay in Figure 4B shows that AR binds to both the
isolated PD and the HD of Pax6, but with highest affinity to the PD.
Adding synthetic androgen (R1881) did not affect the interactions
significantly. Neither did addition of benzonase (Figure S2). Hence,
the interactions are not dependent on DNA-binding.
To map the region of AR responsible for mediating the
reaction, three various AR deletions were constructed; the 500
amino acids long NTD (N-term), the 180 amino acids long central
part including the DBD and the hinge region (Central), and the
239 amino acids long C-terminal LBD (C-term) (Figure 4C). The
GST pulldown assay in Figure 4D shows that full-length Pax6
interacts strongly with the central part of AR. Again, adding
synthetic androgen did not affect the binding. The interaction
between AR(central) and Pax6 is further strengthened by pulldown
assays showing that also other Pax proteins interact with this part
of AR (Figure S3).
The central region of AR was further split in the 50 amino acids
N-terminal to the DBD (N-DBD), the 90 amino acids long DBD,
Figure 4. Mapping of the Pax6-AR interaction in vitro. (A) Schematic illustration of Pax6. Pax6 consists of two DNA-binding domains (DBDs), the
N-terminal paired domain (PD), the paired-type homeodomain (HD) and a C-terminal transactivation domain (TAD). (B) AR interacts with the DBDs of
Pax6. GST, GST-Pax6(PD) and GST-Pax6(HD) were immobilized on glutathione-sepharose beads and used to pull down in vitro translated
35S-
methionine labeled AR in the presence or absence of 10
27 M R1881. The samples, 1% input, and a molecular weight marker (MWM) were run on 10%
SDS-polyacrylamide gels and stained with Coomassie brilliant blue (CBB) (lower panel). Signal from
35S-labeled proteins was detected with a Fujifilm
bioimaging analyzer FUJI-BAS5000 (upper panel). (C) Schematic illustration of AR. The N-terminal domain (NTD), the central DBD, and the C-terminal
ligand-binding domain (LBD) are illustrated. The arrows indicate the different deletion constructs made, with their size in number of amino acids
given in parenthesis. (D) Pax6 binds to the central part of AR. GST, GST-AR(N-term), GST-AR(Central) and GST-AR(C-term) immobilized on glutathione
sepharose beads were used to pull down in vitro translated
35S-methionine labeled Pax6 in the presence or absence of 10
27 M R1881. Upper panel
shows the amount of
35S-labeled Pax6 pulled down, and the lower panel shows the CBB staining of the GST fusion proteins. (E) Further mapping of
the Pax6-AR interaction shows that Pax6 interacts with the DBD of AR. The interaction is reduced by deleting the PD of Pax6, but not by deleting the
HD. The indicated AR constructs fused to MBP were used to pull down in vitro translated
35S-methionine labeled Pax6, Pax6DPD and Pax6DHD as
described. The upper gel pictures show the detected signal from
35S-labeled proteins, and the lower gel pictures show the CBB staining of the MBP
fusion proteins. All results are representative of three independent experiments.
doi:10.1371/journal.pone.0024659.g004
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proteins of the three constructs were used to pull down in vitro
translated Pax6. Compared to the flanking regions, full-length
Pax6 interacted strongly with the DBD of AR (Figure 4E, upper
panels). Deleting the PD of Pax6 (Pax6DPD) reduced this
interaction significantly (Figure 4E, middle panels), while deleting
the HD (Pax6DHD) did not affect the interaction (Figure 4E,
lower panels). In conclusion, the interaction between AR and Pax6
is mainly between the DBD of AR and the PD of Pax6, and is
neither dependent on androgens nor DNA.
SPBP interacts with the DBD of AR
Since SPBP is reported to interact with ERa and here is found to
function as a coactivator of AR, we asked whether SPBP was able to
associate with AR in cells. HeLa cells were transiently cotransfected
with EGFP-AR and HA-SPBP expressing plasmids. An anti-GFP
antibody was used to precipitate EGFP-tagged AR from cell lysates,
and immunoblotting performed using an anti-SPBP antibody [10].
The upper panel in Figure 5A shows that SPBP coprecipitates with
EGFP-AR in HeLa cells stimulated with R1881, but not in
unstimulated HeLa cells. The lower panel in Figure 5A confirms
precipitation of EGFP-AR in extracts both from stimulated and
unstimulated HeLa cells. This strongly suggests that SPBP interacts
with AR in the nucleus of human cells.
The interaction between the full length proteins were confirmed
by coimmunoprecipitation of in vitro translated proteins (Figure 5B),
followed by mapping of the interacting regions using pulldown
assays. First, various regions of AR (schematically illustrated in
Figure 4C) were expressed and purified from E. coli as GST or
MBP fusion proteins while full-length SPBP were produced in vitro
in the presence of
35S-methionine. The pulldown assays in
Figure 5B and 5C show that SPBP, like Pax6, interacts with the
central region, and more specifically the DBD, of AR. A weak
interaction between SPBP and the C-terminal part of AR was also
detected. The interactions are not affected by the presence or
absence of synthetic androgen.
SPBP was then split in parts, as indicated in Figure 5D, in vitro
translated and used in pulldown assays together with the central
part of AR fused to GST. The results of these pulldowns show that
amino acids 1333–1666 of SPBP exclusively interacted with
AR(Central) (Figure 5E). Interestingly, the 1333–1666 region of
SPBP contains its DBD and also the region (1576–1601) that
mediates the interaction with ERa [11]. In addition, this region
encompasses three highly conserved motifs (D-box, E-box, and
AT-hook). To determine whether DNA binding was important for
the SPBP-AR interaction to take place, benzonase was included in
some of the GST pulldown assays. However, adding this
endonuclease did not have any impact on the binding (Figure
S2). Hence, here we have mapped a DNA-independent interaction
between AR and SPBP, mediated by the DBD of AR and the
1333–1666 region of SPBP containing its DBD.
Pax6 and SPBP compete for binding to AR(DBD)
The findings that coexpression of Pax6 repressed SPBP-
mediated transactivation of AR activity, inhibited association of
SPBP with an AR target promoter, and that both SPBP and Pax6
interacted with the same domain of AR, prompted us to
investigate whether there could be a competition between Pax6
and SPBP for AR(DBD) binding. In an attempt to study this, MBP
pulldown assays were performed with increasing amounts of
SPBP(1333–1960) together with constant amounts of full length
Pax6 and MBP-AR(DBD) immobilized on amylose resin. The
1333–1960 region of SPBP binds equally well to AR(DBD) as the
full length protein (data not shown), and was therefore used in this
assay to reduce the migration differences between Pax6 and SPBP.
As shown in Figure 6, Pax6 and SPBP may in fact compete for
binding to AR(DBD). Increasing amounts of SPBP reduce the
amount of Pax6 coprecipitated with MBP-AR(DBD) while the
amount of SPBP binding to AR(DBD) is increased. On the other
hand, presence of Pax6 reduces the amount of SPBP bound to
AR(DBD) (Figure 6B, right). Taken together, these results suggest
that there is a competition between Pax6 and SPBP for binding to
AR, and that this competition is a possible mechanism for the
repressive effect Pax6 has on SPBP-mediated transactivation of
AR activity.
Discussion
AR is critically dependent on recruitment of coactivators and
corepressors for transcriptional regulation of its target genes. The
differential interaction of AR with various cofactors appears to
control the fine balance between proliferation and differentiation
important for maintenance of the normal prostate. Changes in
cofactor levels may shift the balance between suppressing or
facilitating cancer progression (reviewed in [38–40]). In this study,
we have identified the transcriptional coregulator SPBP as a
coactivator of AR, stimulating AR-mediated transcription of the
probasin promoter and enhancing the expression of the AR target
gene PSA in androgen stimulated LNCaP cells. SPBP is expressed
in most cell lines, but highly expressed in the androgen dependent
cancer cell line LNCaP. In normal prostate tissue, both SPBP and
AR are found in glandular cells (www.proteinatlas.org), and we
show that overexpressed AR and SPBP have very similar nuclear
distribution patterns in cells stimulated with androgen. Interest-
ingly, 30% of the prostate cancer samples in the Human Protein
Atlas (www.proteinatlas.org) display a significant enrichment of
nuclear SPBP. Since coregulators of nuclear hormone receptors
often have the ability to influence the activity of multiple receptors
[38], the AR-SPBP association is strengthened by the previously
reported interaction between SPBP and phosphorylated ERa [11].
The developmental transcription factor Pax6 was recently
reported to act as a repressor of androgen stimulated AR activity
[29]. Here we show that Pax6 in addition inhibits SPBP-mediated
stimulation of AR activity and the association of SPBP with an AR
target promoter. Both Pax6 and SPBP were found to associate
with AR in androgen stimulated cells, and their distribution
patterns in the cell nucleus were completely overlapping. Mapping
of interacting regions revealed that all three proteins use their
DBDs to mediate the interactions. Pax6 contains two DBDs, the
PD and the HD. Although both domains are able to interact with
AR, the PD seems to bind more strongly. The interaction between
Pax6 and AR(DBD) correlates well with the fact that other Pax
proteins also interact with the central region of AR. It also
correlates with a recent report showing that the HD protein
HoxB13 represses AR activity by interacting with the AR(DBD)
[41]. The interacting region was in this case mapped using
AR(DBD) point mutations in a mammalian two-hybrid assay.
Interestingly, our in vitro competition assays indicated that SPBP
and Pax6 compete for AR(DBD) binding. Several AR coactivators
are reported to interact with the AR(DBD) (reviewed in [38,39]).
Our results suggest that the inhibitory effect of Pax6 on AR-
mediated transcriptional activity is obtained by masking coacti-
vator binding sites in or displacing coactivators binding to the
DBD of AR. This is in line with recent reports on the
homeoproteins HOXB13 [41] and HOXC8 [42]. Both proteins
act as repressors of AR-mediated transcriptional activity.
HOXB13 significantly reduced the recruitment of AR coactivators
to specific AR target genes, while HOXC8 was shown to block
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24659Figure 5. AR and SPBP interact in cells and in vitro. (A) SPBP coprecipitates with AR in R1881-stimulated HeLa cells. pDestEGFP-AR and
pDestHA-SPBP were cotransfected into HeLa cells grown in medium with or without R1881. The proteins were precipitated using an anti-GFP
antibody (Abcam), separated by SDS-PAGE and visualized by anti-SPBP antibody [10] (upper panel) and anti-GFP antibody (lower panel). (B) SPBP and
AR interact in vitro. HA-SPBP and GFP-AR were in vitro translated in the presence of
35S-methionine and immunoprecipitated using anti-SPBP
antibody or preimmune serum. Precipitated complexes and 10% input of the in vitro translated proteins were resolved by SDS-PAGE. (C) SPBP
interacts with the central part of AR. The indicated AR deletion constructs were expressed as GST fusion proteins, and used to pull down in vitro
translated
35S-methionine labeled SPBP. Upper panel shows the
35S-labeled proteins, and lower panel CBB staining of the GST fusion proteins. (D)
SPBP interacts with the AR(DBD). The central part of AR was divided into three; DBD, N-DBD and hinge. MBP fusions of the indicated AR constructs
were used to pull down
35S-methionine labeled SPBP. Upper panel shows
35S-labeled SPBP, while lower panel shows CBB staining of the MBP fusion
proteins. (E) Schematic illustration of SPBP. SPBP contains an N-terminal TAD, a DBD containing an AT-hook motif (AT), a C-terminal extended plant
homeodomain (ePHD), three nuclear localization signals (NLS) and two glutamine rich regions (Q1 and Q2). The boxes labeled A-G represent
conserved regions. SPBP constructs used in this study are indicated with arrows and number of amino acids. (F) Amino acids 1333–1666 of SPBP
interact with the central part of AR in vitro. The indicated regions of SPBP were in vitro translated and used in pull down assays with GST or GST-
AR(Central). Coprecipitations were detected as described in D. All results are representative of three independent experiments.
doi:10.1371/journal.pone.0024659.g005
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They also found that overexpression of SRC-3 reverses the
HOXC8-mediated blockage. This is similar to our results,
demonstrating that increased SPBP expression partly restores the
Pax6-mediated inhibition.
Understanding the detailed mechanisms and mapping the
specific amino acids important for these interactions and
competitions may have a potential in the future development of
targeted therapies against prostate cancer. AR plays an important
role in both early and advanced stages of prostate cancer etiology.
Formation of active AR-directed transcription complexes occurs
via a sequential recruitment of coactivators [38–40] and alteration
in expression and function of an expanding number of cofactors
are suggested to underlie pathological conditions. Hence, targeting
coregulators for new therapeutics represent a new opportunity
(reviewed in [38]). Importantly, cofactors have been suggested to
play important roles in the development of androgen insensitive
prostate cancer [43], by enhancing the ability of AR to maintain
sufficient function in a low androgen environment for mainte-
nance of cell growth and survival. A putative strategy to inhibit or
diminish recruitment of coactivators to the receptor is to mimic the
AR-Pax6 interaction in cancer cells. One possibility may be to use
peptides representing the Pax6 interaction surface. A promising
study using a peptide that mimics the function of the short splice
variant of the coregulator MTA1 is shown to sequester ERa in the
cytoplam [44]. The MTA1s peptide had the ability to inhibit ERa-
mediated transactivation, estrogen-dependent proliferation, an-
chorage-independent growth and in vivo tumor progression [45].
This indicates that development of peptides abrogating receptor-
coactivator interactions may have therapeutical opportunities.
We found that Pax6 and SPBP colocalized with AR in the
nucleus of androgen stimulated cells overexpressing the proteins.
But since the expression of Pax6 and AR in various tissues is very
restricted, few tissues coexpress them both. AR is highly expressed
in the epithelium of the tear producing lachrymal glands
surrounding the eyes [1], where also Pax6 is found. The expression
patterns of AR and PAX6 during development of the pituitary have
a transient overlap along the midline border [46,47]. Since the
pituitary is the superior hormone-producing gland of the body, a
possible common function for Pax6 and AR in this organ is to
coparticipate in expression of hormones. Likewise, AR is
coexpressed with Pax6 in distinct pyramidal neurons of the
hippocampus [48,49], in neurons and astrocytes of the developing
and adult forebrain [50,51], as well as in the dopamine-producing
substantia nigra of the midbrain [52,53]. Furthermore, our data
show that Pax6 and AR are coexpressed in the androgen
insensitive prostate cancer cell line PC3, the lens epithelial cell
line B3, in addition to the cancer cell lines HEK293 and HeLa.
Hence, the Pax6-mediated repression of AR activity may be
important and relevant in certain tissues, and also in specific
cancer cells aberrantly expressing both proteins.
In conclusion, SPBP and Pax6 modulate AR activity by using
their DBDs to interact with the DBD of AR. Elucidating the
specific mechanisms involved in the competition between Pax6
and SPBP for binding to AR, may result in important knowledge
in the field of targeting AR coregulators for new cancer
therapeutics.
Supporting Information
Figure S1 Expression levels of exogenous HA-AR, HA-
SPBP and HA-Pax6 in HEK293 cells. Subconfluent HEK293
cells in a 6 well dish (Nunc) were cotransfected with pDestHA-AR
(375 ng), pDestHA-SPBP (1.5 mg), and pDestHA-Pax6 (250 ng),
and stimulated with 10
27 M R1881. The cells were harvested in
26SDS gel loading buffer approximately 20 hours after transfec-
tion, proteins separated by SDS-PAGE and visualized by Western
Blotting using mouse anti-HA (1:1.000, clone 12CA5, Roche)
antibody. Stars indicate unspecific bands.
(TIF)
Figure S2 The interaction between Pax6 and AR or
SPBP and AR is not dependent on DNA. GST, GST-
AR(Central), and GST-AR(DBD) immobilized on glutathione
sepharose beads were used to pull down in vitro translated
35S-
labeled Pax6 (A) and SPBP (B) in the presence or absence of
benzonase. The strength of the interactions is unaffected by
removing DNA from the reactions.
(TIF)
Figure 6. Pax6 and SPBP compete for binding to AR(DBD). (A)
MBP-AR(DBD) immobilized on amylose resin beads were incubated with
constant amounts of
35S-labeled HA-Pax6 and increasing amounts of
HA-SPBP(1333–1960). The upper gel picture shows the signal detected
for the
35S-labeled proteins, and the lower gel picture shows the
amount of MBP fusion proteins (CBB staining). The numbers above the
upper gel picture indicate how many ml that were used of each in vitro
translated protein. The presented result is representative of three
independent experiments. (B) Quantification based on the average fold
binding of three independent experiments. The quantification was
performed using Image Gauge version 4 from FUJI. Left panel: The
amount of Pax6 bound to MBP-AR(DBD) was set to 1 fold binding.
Increasing the concentration of SPBP while keeping the amount of Pax6
constant, results in reduced binding of Pax6 to the AR(DBD). Right
panel: The amount of SPBP bound to MBP-AR(DBD) was set to 1 fold
binding. Coincubation of Pax6 and SPBP with AR(DBD) reduces the
amount of SPBP bound to AR. The binding is rescued by increasing
amounts of SPBP, while keeping the input of Pax6 constant.
doi:10.1371/journal.pone.0024659.g006
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family interact with the central region of AR. GST and
GST-AR(Central) immobilized on glutathione sepharose beads
were used to pull down in vitro translated
35S-labeled members of
the Pax family. The results show that all Pax proteins tested bind
to the central region of AR.
(TIF)
Table S1 Plasmids used in this study.
(DOC)
Table S2 Oligonucleotides used in this study.
(DOC)
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